Inside a sugar factory in Aarberg, Switzerland—a town of roughly 4,000 people best known for beets and industrial-scale refining—sits a 50,kiloliter bioreactor that Planetary believes could change the economics of alternative protein. The equipment doesn't belong to Planetary, exactly. The Geneva-based startup licensed the technology to Schweizer Zucker AG, the sugar producer, and by December 2024 the installation was churning out mycoprotein from molasses and other sucrose byproducts: up to 2,200 metric tons annually, with a reported carbon footprint of 2.67 kg CO2e per kilogram of finished product.
Seven months later, that protein—branded as Libre, following Planetary's acquisition of Libre Foods in June 2025—was on shelves at approximately 242 ALDI Suisse stores in the form of a chicken-alternative filet. Mid-April 2026 brought another milestone: a CHF 22 million Series A (roughly $28 million), co-led by Radikal Capital and Oetker Ventures, with participation from arc investors, Green Generation Fund, AgriFoodTech Venture Alliance, and existing backers Astanor Ventures and XAnge. Royal Cosun, which had invested CHF 3 million in October 2024, also joined.
The structure of the financing tells you something about where Planetary sits in the funding landscape. CHF 16 million came in equity; another CHF 6 million arrived as credit facilities. Total capital raised since the company's 2021 founding now stands at approximately CHF 32 million in equity—not extravagant by biotech standards, but enough to underwrite a licensing model that sidesteps the heaviest capital expenditures.
The Bet on Asset-Light Expansion
Planetary isn't aiming to build and operate sprawling fermentation plants. Instead, the company's BioBlocks platform gets licensed to sugar producers and agro-industrial partners—facilities already equipped with the infrastructure and feedstock to support fermentation. The pitch is straightforward: convert side-streams (molasses, sucrose remnants) into high-value ingredients. Plug the technology into existing sugar mills. Turn waste into protein.
It's a model that, in theory, avoids the punishing capital intensity that has bedeviled much of the alternative protein sector. Total private funding across alt-protein hit approximately $881 million USD in 2025, according to the Good Food Institute—a far cry from the multi-billion-dollar peaks of earlier years. Investors have grown wary of moonshot manufacturing plays. Planetary's licensing approach offers a different wager: decentralized production, local partnerships, lower upfront investment.
The new capital will bankroll international expansion of this strategy. Planetary has set a provocative target: push mycoprotein production costs below $1 per kilogram in sugar-rich, protein-deficient regions. Discussions with India's Dhampur Bio Organics have been mentioned, though no binding agreement has surfaced publicly.
Whether that sub-dollar threshold is achievable remains an open question. The Aarberg facility provides proof of concept, certainly, but replicating the model across geographies with disparate infrastructure, regulatory frameworks, and supply-chain realities is another matter entirely.
18 Months to Prove It
Planetary's timeline is aggressive. The company has publicly committed to reaching asset-level profitability within 18 to 24 months—a target that hinges on both operational scale and product diversification beyond mycoprotein. Co-founder and CEO David Brandes brings relevant scar tissue to the endeavor: he previously co-founded Peace of Meat, a cultivated-meat startup acquired by Meat-Tech/Steakholder Foods in 2020, navigating the capital-intensive biotech grind before. Chief Scientific Officer Ian Marison adds four decades of industrial fermentation expertise to the mix.
The profitability clock matters. Venture patience for pre-revenue or low-margin biotech has thinned considerably. Planetary's licensing model, if it works, could generate revenue without the balance-sheet drag of owning and operating production assets. But "if it works" carries weight. Sugar producers need to see clear ROI on byproduct conversion. Partners in emerging markets need technical support, supply-chain coordination, regulatory navigation. Licensing fees and royalties only flow if the installations actually scale.
Recognition has come, at least on the innovation front. Planetary won a WIPO Global Award in 2025 for BioBlocks and secured a CHF 1.8 million grant from Innosuisse earlier that same year. Awards are useful for credibility; they don't guarantee market traction.
The Next Test
With production validated in Switzerland and retail distribution locked in through ALDI, Planetary now confronts the harder part: proving the model can travel. The sub-$1/kg cost target isn't just about fermentation efficiency—it requires partnerships with sugar producers willing to retrofit facilities, regulatory pathways that don't strangle timelines, and logistics that can handle perishable protein ingredients in regions where cold chains aren't a given.
The bioeconomy thesis—turn agricultural waste into high-value products, decentralize production, lower costs through localization—has intellectual appeal. Execution is murkier. India, for instance, offers enormous sugar production and a protein gap, but also fragmented supply chains and varied food-safety infrastructure. Europe's sugar industry is mature and regulated; emerging markets present different variables.
Perhaps Planetary's advantage is that it doesn't need to solve everything itself. Licensing means local partners carry much of the operational risk. But it also means Planetary's revenue depends on their success—a model that scales only if the BioBlocks platform truly delivers plug-and-play economics.
The 18-to-24-month profitability window will clarify a lot. Either the licensing flywheel accelerates—more partners, more installations, margin expansion—or the model hits friction points that weren't visible in a controlled Swiss sugar factory. For a sector starved of viable paths to profitability, Planetary's bet is worth watching. The real question isn't whether the technology works. It's whether the business model does.
